Case Study: Leveraging Wyeth expertise to make a great product even better

Methylnaltrexone (MNTX)

Partner: Progenics Pharmaceuticals, Inc.

• MNTX was licensed in December 2005
• The Wyeth and Progenics clinical teams work closely together to develop indications that meet the therapeutic needs of wider patient populations
• Wyeth contributed its formulation expertise to develop an improved SC formulation—stable at room temperature in pre-filled syringes—and a completely new oral formulation
• Wyeth’s team is accelerating the global development program while maximizing commercial value